Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the biotech's neurotropic adeno-associated virus capsid in efforts to develop a ...

When Taylor Swift fans found out Lily Tomlinson was dying from a rare and aggressive brain tumor, they stepped up to comfort ...

Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & Hers ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and people of color in movies and TV. Now, Eli Lilly is hoping to spark a ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Lily Collins may be a busy new mom, but that hasn’t stopped her from delivering a chic look. Last night, the Emily in Paris ...

LILY Phillips has shared a new video boasting about her shooting with Playboy. The 23-year-old adult content creator took to TikTok to show off her new gig and was clearly thrilled about working ...

Eli Lilly (LLY) closed the latest trading day at $822.51, indicating a -0.27% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 1.07%.

Investing.com -- Eli Lilly and Company (NYSE:LLY) CEO David Ricks spoke to the BBC about the long-term effects of the Trump administration’s sweeping tariffs on imports, in the first comments ...

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...